Characterization of Real World Treatment Patterns and Outcomes Among Older Adults with Chronic Lymphocytic Leukemia in the Pre Novel-Agents Era: An Analysis of the 2007-2013 SEER-Medicare Database
Mato A, Jahnke J, Li P, Mehra M, Ladage V, Mahler M, Huntington S, Doshi J. Characterization of Real World Treatment Patterns and Outcomes Among Older Adults with Chronic Lymphocytic Leukemia in the Pre Novel-Agents Era: An Analysis of the 2007-2013 SEER-Medicare Database. Blood 2016, 128: 4773. DOI: 10.1182/blood.v128.22.4773.4773.Peer-Reviewed Original ResearchChronic lymphocytic leukemiaOlder CLL patientsOverall survivalTreatment initiationCox regressionCLL patientsClinical trialsFirst treatmentNovel agentsChlorambucil monotherapyOlder adultsLymphocytic leukemiaMedicare feeClinical practiceLow-income subsidy statusReal-world treatment patternsRecent landmark clinical trialsCLL/SLL patientsLogistic regressionOlder individualsAdvisory CommitteeGilead SciencesReal-world outcome dataAnemia/thrombocytopeniaApproval of ibrutinibHigh cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia.
Doshi JA, Li P, Huo H, Pettit AR, Kumar R, Weiss BM, Huntington SF. High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia. The American Journal Of Managed Care 2016, 22: s78-86. PMID: 27270157.Peer-Reviewed Original ResearchConceptsChronic myeloid leukemiaTyrosine kinase inhibitorsHigher cost sharingMedicare Part DDrug initiationMyeloid leukemiaLIS patientsInitiation of TKIsRetrospective claims-based analysisOral tyrosine kinase inhibitorNon-LIS patientsMonths of diagnosisClaims-based analysisPart DLow-income subsidyTKI claimsD patientsCox regressionMedicare claimsPatientsCritical therapyBenefit phasePocket costsSpecialty drugsCost sharing